Peninsula vaccine maker targets $100M IPO — but not for Covid

Vaxcyte's chairman is the leader of the White House's Operation Warp Seed public-private initiative to deliver a Covid-19 vaccine, but the company is centering its IPO bid on a vaccine for pneumonia.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.